摘要
难治性抑郁症用抗抑郁药合并新型抗精神病药治疗作为增效手段,是当前研究热点之一。新型抗精神病药利培酮、奥氮平、喹硫平、齐拉西酮、阿立哌唑分别与抗抑郁药西酞普兰、舍曲林、帕罗西汀、艾司西酞普兰及氟伏沙明合用治疗难治性抑郁症,均采用汉密尔顿抑郁量表(HAMD-17)评定治疗效果,治疗结束后两组HAMD评分均显著降低,以研究组疗效较好而快,显示抗抑郁药合用新型抗精神病药治疗难治性抑郁症优于单用抗抑郁药。其机制与新型抗精神病药对5-羟色胺受体的阻断作用或对多巴胺及去甲肾上腺素的影响有关。作者对近年来国内外有关合用新型抗精神病药治疗难治性抑郁症的部分报道综述如下。
The combination of antidepressants and atypical antipsychotic drugs that is used as the augmenting agents of treatment-resistant depression （ TRD） is a research focus at present. The atypical anfipsychotic drugs of risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole respectively combined with antidepressants of citalopram, sertraline, paroxitine, escitalopram and fluvoxamine were applied to treat TRD. HAMD-17 was adopted to the evaluation of efficacy. After treatment, both groups had a dramatically reduction of depressive scores by HAMD scales, and the study groups had better and quicker effect recoveries （ P 〈 0.01 ）. It is indicated that the efficacy of combination of antidepressants and atypical antipsychotic drugs for TRD is better than that of single antidepressants. The antipsychotic drugs can block 5-HT receptor, and impact the actions of dopamine and NE, which may he the mechanism of its efficacy. The author reviews a series of trials performed at home and abroad in recent years on combined application of atypical antipsychotic drugs for TRD.
出处
《职业与健康》
CAS
2012年第17期2154-2155,2158,共3页
Occupation and Health
关键词
新型抗精神病药
难治性抑郁症
Atypical antipsychotic drugs
Treatment-resistant depression （ TRD ）
作者简介
班娜，女，主治医师，主要从事精神病学临床工作。
